Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + tegafur + gimeracil + oteracil
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anlotinib + tegafur + gimeracil + oteracil is a combination therapy being investigated for the treatment of advanced pancreatic cancer. Anlotinib is a small-molecule multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor angiogenesis and proliferation by inhibiting VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit. The other components—tegafur, gimeracil, and oteracil—constitute the oral fluoropyrimidine S-1. Tegafur is a prodrug of 5-fluorouracil (5-FU); gimeracil inhibits dihydropyrimidine dehydrogenase (DPD) to prevent the degradation of 5-FU; and oteracil inhibits orotate phosphoribosyltransferase (OPRT) to reduce 5-FU-induced gastrointestinal toxicity. This combination aims to provide synergistic antitumor activity by combining anti-angiogenic effects with potent, well-tolerated chemotherapy. It is primarily being developed by the Cancer Hospital Affiliated to Guangxi Medical University for patients who have failed first-line chemotherapy.
- Brand names
- Focus V
- Other names
- Anlotinib plus S-1Anlotinib + S-1
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)OPRT (Orotidine 5'-phosphate decarboxylase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + tegafur + gimeracil + oteracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + tegafur + gimeracil + oteracil.